Lymphangiogenesis in kidney cancer: Expression of VEGF-C, VEGF-D and VEGFR-3 in clear cell and papillary renal cell carcinoma

Oncology Reports

Volumn 20, Issue 4, 2008, Pages 721-725

  Bierer, Stefan ^a   Herrmann, E ^a   Kopke T ^a   Neumann, J ^b   Eltze, E ^b   Hertle, L ^a   Wulfing C ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Clear cell; Immuno histochemistry; Lymphangiogenesis; Papillary; Renal cell carcinoma; Vascular endothelial growth factor

Indexed keywords

POLYCLONAL ANTIBODY; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 3;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CLEAR CELL CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; DRUG TARGETING; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CANCER; KIDNEY CARCINOMA; LYMPH NODE METASTASIS; LYMPHANGIOGENESIS; MICROARRAY ANALYSIS; NEPHRECTOMY; OVERALL SURVIVAL; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; LYMPHANGIOGENESIS; MIDDLE AGED; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR D; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 54949113912     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or_00000065     Document Type: Article

References (21)

1. Chow WH, Devesa SS, Warren JL and Fraumeni JF Jr: Rising incidence of renal cell cancer in the United States. JAMA 281: 1628-1631, 1999.
2. Pantuck AJ, Zisman A and Belldegrun AS: The changing natural history of renal cell carcinoma. J Urol 166: 1611-1623, 2001.
3. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124, 2007.
4. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125-134, 2007.
5. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, et al: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271-2281, 2007.
6. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, et al: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370: 2103-2111, 2007.
7. Karakiewicz PI, Trinh QD, Bhojani N, Bensalah K, Salomon L, de la Taille A, Tostain J, et al: Renal cell carcinoma with nodal metastases in the absence of distant metastafic disease: prognostic indicators of disease-specific survival. Eur Urol 51: 1616-1624, 2007.
8. Canfield SE, Kamat AM, Sanchez-Ortiz RF, Detry M, Swanson DA and Wood CG: Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease (clinical stage TxN 1-2M0): the impact of aggressive surgical resection on patient outcome. J Urol 175: 864-869, 2006.
9. Achen MG, Mann GB and Stacker SA: Targeting lymphangiogenesis to prevent tumour metastasis. Br J Cancer 94: 1355-1360, 2006.
10. Wülfing P, Kersting C, Tio J, Fischer RJ, Wülfing C, Poremba C, Diallo R, et al: Endothelin-1-, endothelin-A-, and endothelin-B-receptor expression is correlated with vascular endothelial growth factor expression and angiogenesis in breast cancer. Clin Cancer Res 10: 2393-2400, 2004.
11. Sundar SS and Ganesan TS: Role of lymphangiogenesis in cancer. J Clin Oncol 25: 4298-4307, 2007.
12. Shayan R, Achen MG and Stacker SA: Lymphatic vessels in cancer metastasis: bridging the gaps. Carcinogenesis 27: 1729-1738, 2006.
13. Stacker SA, Williams RA and Achen MG: Lymphangiogenic growth factors as markers of tumor metastasis. APMIS 112: 539-549, 2004.
14. Makinen T, Veikkola T, Mustjoki S, Karpanen T, Catimel B, Nice EC, Wise L, et al: Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J 20: 4762-4773, 2001.
15. Juttner S, Wissmann C, Jons T, Vieth M, Hertel J, Gretschel S, Schlag PM, et al: Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol 24: 228-240, 2006.
16. Aishima S, Nishihara Y, Iguchi T, Taguchi K, Taketomi A, Maehara Y and Tsuneyoshi M: Lymphatic spread is related to VEGF-C expression and D2-40-positive myofibroblasts in intrahepatic cholangiocarcinoma. Mod Pathol (In press).
17. Gunningham SP, Currie MJ, Han C, Turner K, Scott PA, Robinson BA, Harris AL, et al: Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia. Cancer Res 61: 3206-3211, 2001.
18. Bando H, Brokelmann M, Toi M, Alitalo K, Sleeman JP, Sipos B, Grone HJ, et al: Immunodetection and quantification of vascular endothelial growth factor receptor-3 in human malignant tumor tissues. Int J Cancer 111: 184-191, 2004.
19. Lin J, Lalani AS, Harding TC, Gonzalez M, Wu WW, Luan B, Tu GH, et al: Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res 65: 6901-6909, 2005.
20. Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, Eble JN, et al: The Heidelberg classification of renal cell tumours. J Pathol 183: 131-133, 1997.
21. Van der Auwera I, Cao Y, Tille JC, Pepper MS, Jackson DG, Fox SB, Harris AL, et al: First international consensus on the methodology of lymphangiogenesis quantification in solid human tumours. Br J Cancer 95: 1611-1625, 2006.